Abstract
Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 570-575 |
| Number of pages | 6 |
| Journal | Journal of Biological Response Modifiers |
| Volume | 9 |
| Issue number | 6 |
| State | Published - 1990 |
| Externally published | Yes |
Fingerprint
Keywords
- Ara-C
- Chemotherapy
- Granulocyte/macrophage colony-forming cells
- Interferon
- Leukemia
ASJC Scopus subject areas
- Cancer Research
- Immunology
- Pharmacology
Cite this
Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity. / Richman, Carol M; Slapak, C. A.; Toh, B.
In: Journal of Biological Response Modifiers, Vol. 9, No. 6, 1990, p. 570-575.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity
AU - Richman, Carol M
AU - Slapak, C. A.
AU - Toh, B.
PY - 1990
Y1 - 1990
N2 - Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.
AB - Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.
KW - Ara-C
KW - Chemotherapy
KW - Granulocyte/macrophage colony-forming cells
KW - Interferon
KW - Leukemia
UR - http://www.scopus.com/inward/record.url?scp=0025647121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025647121&partnerID=8YFLogxK
M3 - Article
C2 - 1705960
AN - SCOPUS:0025647121
VL - 9
SP - 570
EP - 575
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1524-9557
IS - 6
ER -